Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

253 results about "Chronic inflammatory disease" patented technology

A patient is diagnosed with chronic inflammatory disease when inflammation occurs at various sites within the body over a long period of time. This inflammation can be within the arteries or other organs, and can lead to rheumatoid arthritis and psoriasis.

Amine Compounds

InactiveUS20080200535A1Potent immunosuppressive actionBiocideSenses disorderUveitisAutoimmune disease
There is provided a compound exhibiting an activity of suppressing immune response with reduced adverse drug reactions, which compound is useful in the chemotherapy for preventing or treating, for example, a wide range of various autoimmune diseases including systemic erythematodes, chronic rheumatoid arthritis, Type I diabetes, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis or other disorders, or chronic inflammatory diseases, or cancers, lymphoma or leukemia, or resistance to organ or tissue transplantation or rejection against transplantation.Novel amine compounds having an S1P1 / Edg1 receptor agonist effect, possible stereoisomers or racemic bodies of the compounds, or pharmacologically acceptable salts, hydrates or solvates of the compound, the stereoisomers or the racemic bodies, or prodrugs of the compounds, the stereoisomers, the racemic bodies, the salts, the hydrates or the solvates, are provided.
Owner:ASAHI KASEI PHARMA

Chalcone and its analogs as agents for the inhibition of angiogensis and related disease states

The present invention relates to chalcone and chalcone derivatives and analogs which are useful as angiogenesis inhibitors. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good activity as angiogenesis inhibitors. The present invention also relates to the use of chalcone and its analogs as antitumor / anticancer agents and to treat a number of conditions or disease states in which angiogenesis is a factor, incluidng angiongenic skin diseases such as psoriasis, acne, rosacea, warts, eczema, hemangiomas, lymphangiogenesis, among numerous others, as well as chronic inflammatory disease such as arthritis.
Owner:BOWEN J PHILLIP +3

Methods of treating chronic inflammatory diseases using carbonyl trapping agents

InactiveUS6444221B1Improved therapeutic propertyImprove propertiesBiocidePeptide/protein ingredientsEtiologyBenzoic acid
These and other objects of this invention are achieved by providing a novel method and compositions for the clinical treatment of chronic inflammatory diseases. This invention involves use of systemically administered compositions which include primary amine derivatives of benzoic acid as carbonyl trapping agents. These primary therapeutic agents act by chemically binding to and sequestering the aldehyde and/or ketone products of lipid peroxidation. Increased levels of lipid peroxidation have been repeatedly demonstrated as a part of the non-enzymatic "inflammatory cascade" process which underlies the secondary etiology of chronic inflammatory diseases. p-Aminobenzoic acid (or PABA) is an example of the primary therapeutic agent of the present invention. PABA has a small molecular weight, is water soluble, has a primary amine group that reacts with carbonyl-containing metabolites under physiological conditions and is tolerated by the body in relatively high dosages and for extended periods. The carbonyl sequestering agents are used in combination with at least one co-agent so as to produce an additional beneficial physiological effect of an anti-inflammatory nature. Such compositions are administered systemically entirely via the oral route. Co-agents of the present invention include anti-oxidants and free radical trapping compounds (e.g., alpha-tocopherol), compounds having indirect anti-oxidant activity (e.g., selenium), vitamins (e.g., pyridoxine HCl), compounds which facilitate kidney drug elimination (e.g., glycine), metabolites at risk of depletion (e.g., pantothenic acid), sulfhydryl containing chemicals (e.g., methionine), compounds which facilitate glutathione activity (e.g., N-acetylcysteine), and non-absorbable polyamine co-agents (e.g., chitosan).
Owner:SECANT PHARMA

HMB compositions and uses thereof

InactiveUS20050215640A1Reduce tumor growth rateReduce rateBiocideNervous disorderInvoluntary weight lossNeutral Amino Acids
The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ω-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.
Owner:ABBOTT LAB INC

Methods of treating inflammation using antibodies to M-CSF

InactiveUS7108852B2Inhibiting and minimizing capabilityInhibiting and minimizing accumulationSnake antigen ingredientsImmunoglobulins against cytokines/lymphokines/interferonsAutoimmune responsesAutoimmune disease
A hematopoetic factor called “colony stimulating factor” (CSF) is capable of synergizing the attracting capabilities of chemokines and of inducing the accumulation and / or activation in vitro and in vivo of key components of inflammatory responses. Various types of agents that inhibit or otherwise hinder the production, release or activity of CSF could be used therapeutically in the treatment of ischemia and other inflammatory diseases, such as autoimmune disease, and various chronic inflammatory diseases such as rheumatoid arthritis and psoriasis.
Owner:WARNER-LAMBERT CO

Compounds useful as anti-inflammatory agents

Disclosed are compounds useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.
Owner:BOEHRINGER INGELHEIM PHARMA INC

Compositions and Methods for Treating and Preventing Inflammatory and/or Degenerative Processes in Humans and Other Animals

InactiveUS20080317885A1Salicyclic acid active ingredientsBiocideReactive airway diseaseSarcoidosis
Disclosed are compositions useful for treating Alzheimer's disease, atherosclerosis, arteriosclerosis, osteoarthritis and other degenerative joint diseases, Huntington's chorea, Parkinson's disease, optic atrophy, retinitis pigmentosa, macular degeneration, muscular dystrophy, aging-associated degenerative processes, asthma, dermatitis, laminitis, pemphigoid, pemphigus, reactive airway disease (e.g., COPD, IAD), inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), multiple sclerosis, rheumatoid arthritis, periodontal disease, systemic lupus erythematosus, sarcoidosis, psoriasis, type I diabetes, ischemia-reperfusion injury, chronic inflammatory diseases, geriatric wasting, cancer cachexia, cachexia associated with chronic inflammation, sick feeling syndrome, and other inflammatory and / or degenerative diseases, disorders, conditions, and processes in humans and other animals. In one embodiment, the compositions include at least 4 of the following: a MMP1 inhibitor, a MMP2 inhibitor, a MMP3 inhibitor, a MMP7 inhibitor, a MMP9 inhibitor, an ADAMTS-4 inhibitor, a MMP13 inhibitor, and a MMP14 inhibitor. In another embodiment, the compositions include a curcuminoid, a polymethoxylated flavone, a catechin, and a boswellic acid.
Owner:BAKER DONALD J

Novel Pyrimidine- And Triazine-Hepcidine Antagonists

The present invention relates to new hepcidin antagonists, pharmaceutical compositions containing them and the use thereof as a drug, in particular for the treatment of iron metabolism disorders such as, in particular, iron deficiency diseases and anaemia, in particular anaemia associated with chronic inflammatory disease (ACD: anaemia of chronic disease and AI: anaemia of inflammation).
Owner:VIFOR INT AG

Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents

This invention relates to novel processes for preparing heteroaryl-substituted urea compounds of formula (I): which are useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. X, Ar, L, Q and are described herein.
Owner:BOEHRINGER INGELHEIM PHARMA INC

Compounds and methods for use in treating neoplasia and cancer based upon inhibitors of isoprenylcysteine methyltransferase

The present invention relates to a novel method for the treatment of neoplasia, including cancer and other diseases and conditions in humans and mammals. More particularly, in preferred aspects, the present invention provides a method for the use of prenylcysteine analogs for the treatment of neoplasia, hyperproliferative cell growth including psoriasis, restenosis following cardiovascular surgery, hyperplasia, including renal hyperplasia, chronic inflammatory diseases including rheumatoid and osteoarthritis, among others.
Owner:PURDUE RES FOUND INC

Methods for using JNK inhibitors for treating or preventing disease-related wasting

The present invention relates to methods useful for the treatment or prevention of disease-related wasting. The methods of the invention comprise the administration of an effective amount of a JNK Inhibitor. In one embodiment, the disease is HIV, AIDS, cancer, end-stage renal disease, kidney failure, chronic heart disease, obstructive pulmonary disease or tuberculosis. The methods can further comprise the administration of a therapeutic or prophylactic agent useful for the treatment or prevention of HIV, AIDS, cancer, end-stage renal disease, kidney failure, chronic heart disease, obstructive pulmonary disease, chronic infectious diseases (e.g., osteoarthritis and bacterial endocarditis), chronic inflammatory diseases (e.g., scleroderma and mixed connective tissue disease) or tuberculosis.
Owner:CELGENE CORP

Application of cationized polysaccharide in preparation of medicines for bacterial biomembrane control

InactiveCN108938662AActivate the immune defense mechanismStimulate phagocytosisAntibacterial agentsOrganic active ingredientsCell-Extracellular MatrixECM Protein
The invention discloses an application of a cationized polysaccharide, particularly an application of a cationized polysaccharide in preparation of antibacterial biomembrane agents, antibacterial coating / spraying agents for biological medical devices, and antibacterial functional materials. The cationized polysaccharide is a polysaccharide having positive charges and is prepared by reacting a natural polysaccharide with a quaternary ammonium salt or a polyamine compound. The cationized polysaccharide can interact with negative-charge polysaccharides in bacteria and biomembrane extracellular matrixes, has excellent sterilization effects, and can be applied well in chronic inflammation diseases, devices for external use or device surface antibiosis, and antibacterial biological materials such as daily chemical products, package products and household paper containing cationized polysaccharides.
Owner:NANJING UNIV

Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof

Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and / or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and / or known anti-inflammatory drugs, such as aspirin.
Owner:ALFAMA INVESTIGACAO E DESENVOLVIMENTO DE PRODUTOSFARMACEUTICOS LDA

Methods of Treating Chronic Inflammatory Diseases Using a GM-CSF Antagonist

The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of chronic inflammatory disease, such as rheumatoid arthritis. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody, and an anti-folate compounds, e.g., methotrexate, to a patient that has RA and pharmaceutical compositions comprising such antagonists.
Owner:KALOBIOS PHARMA

Kukoline intravenous transfusion preparation

ActiveCN101347408AOvercome the bias that IV route of administration is not possibleSolve the clinical problems prone to anaphylactic shockOrganic active ingredientsAntipyreticClinical efficacyRheumatism
The invention provides a sinomenine injection special for intravenous administration. The sinomenine injection is an injection which comprises 0.005-0.3wt% of sinomenine and an aqueous solvent for injection, or an injection which comprises sterile injection powder or lyophilized injection powder used for preparation just before injection to cause the sinomenine concentration to be 0.005-0.3wt% in the injection and the aqueous solvent for injection. The sinomenine injection of the invention is used for treating rheumatism, chronic pain and other chronic inflammatory diseases. Compared with other existing injection forms, the sinomenine injection special for intravenous injection has lower drug adverse reaction, and the clinical curative effect is obviously improved.
Owner:李蕴麟
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products